Gour Medical, animal health specialist, lists on the Marché Libre Euronext Paris

 Zug (Switzerland) on December 1ST , 2016 – Gour Medical, an animal health specialist , today announces the successful completion of its direct listing on Marché Libre Euronext Paris (ISIN code: CH0342399851; Ticker: MLGML), the French securities market.

Gour Medical is a pharmaceutical company dedicated to the development and marketing of veterinary drugs for mature pets.

Having first identified and acquired a number of drug candidates from the human health industry, Gour Medical has then been able to maximize their clinical and market potential in order to treat mature pets. Gour Medical has signed exclusive and worldwide licensing agreements with several bio-pharmaceutical leaders in human health for the development and marketing of their products for veterinary use. The bio-pharmaceutical leaders include Actelion in Switzerland [SIX Swiss Exchange: ATLN], Medicom Healthcare in the United Kingdom, Solmic Research in Germany and the US-based world leader in animal health diagnostics— Idexx Laboratories, Inc. [NASDAQ: IDXX].

Wide-ranging and innovative product portfolio

Gour Medical’s portfolio includes four innovative products / product lines, some of which will be ready to be marketed shortly:

  • A line of ophthalmological products, with planned market launch during the second half of 2017;
  • Gour-153, a painkiller scheduled to be marketed in 2018;
  • Gour-713 and Gour-419, two products currently under development for the treatment of anxiety and atopic dermatitis respectively.

A growing market

The pet health market, which is currently estimated at € 9.4 billion worldwide, is experiencing strong and consistent growth and is expected to reach more than € 13 billion by 2020 (CAGR +7%). This trend looks sustainable, as pets are increasingly well fed and cared for. Indeed, the life expectancy of dogs’ and cats’ continues to increase and aging animals are the most likely to contract diseases.

Product development and marketing

Gour Medical intends to extend its comprehensive portfolio to prepare for the market launch of its first products and strengthen its team. Gour Medical also intends to take advantage of the dynamism, strong demand and steep growth of its core target: mature pets’ health. Drawing on its successful listing on the Marché Libre Euronext Paris, Gour Medical hopes to attract new investors to support its ambitious development strategy and in due course to transfer its listed shares to Alternext Paris.

Gour Medical’s listing on the Marché Libre

Gour Medical shares are being listed on the Marché Libre Euronext Paris stock exchange through direct listing. The issued share capital of Gour Medical currently comprises 2,830,000 shares. Based on a price per share of €5.69 at the time of listing, the Company’s market capitalization is €16.1 million.

Financial Intermediaries and Advisors

 gour medical aurgalys  gour medical lexelians  gour medical python
Listing Sponsor Financial Advisor Legal Advisor

 

Contacts
animaux thérapeutiques

 

 

Serge Goldner

CEO

Tél. : +41 435 08 00 72

contact@gour-medical.com

 

Gour Medical Alize

Presse

Caroline Carmagnol / Wendy Rigal

Tél. : +33 (0)1 44 54 36 66

gourmedical@alizerp.com

 

Download PDF version of this PR